Altair Nanotechnologies Inc. has entered into a commercial research agreement with the Elanco Animal Health Division of Eli Lilly and Company. The agreement provides Elanco with exclusive rights to develop animal health products using Altairnano’s nanotechnology-based products.
The agreement provides a schedule for expedient progress from development and proof of concept to readying products for clinical trials and regulatory approval.
Altairnano is an innovator and supplier of advanced ceramic nanomaterials. The company focuses on nanotechnology applications to enable new potentially high-growth markets.
In alternative energy, Altairnano is pioneering new battery materials and systems. The company is applying nanotechnology to the development of drug candidates for humans and companion animals, coatings materials for implants, and materials for dental applications.
Its high performance nanomaterials have applications in paints, coatings, and the treatment of water and air.
Elanco is a global research-based animal health company that develops and markets products to improve the health and production of animals in more than 100 countries. Elanco is a division of Eli Lilly and Company, a leading innovation-driven pharmaceutical corporation. Elanco products enhance animal health, wellness, welfare and performance.